TG Therapeutics: 3 Key Takeaways for Long-Term Investors
TG Therapeutics' executives expressed confidence in BRIUMVI's long-term growth potential, citing expanded patient reach, existing commercial infrastructure, and a long patent runway. The company has $557 million in cash and investments, with patent protection extending into the mid-2040s, providing financial flexibility for pipeline progress and share repurchases.






